• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

使用[铜]Cu-NOTA-Trodelvy对膀胱癌中Trop2表达进行免疫正电子发射断层显像。

ImmunoPET Imaging of Trop2 Expression in Bladder Cancer Using [Cu]Cu-NOTA-Trodelvy.

作者信息

Huang Wenpeng, Wang Tianyao, Chao Fangfang, Yang Qi, Mixdorf Jason C, Li Liming, Engle Jonathan W, Fan Yu, Kang Lei, Cai Weibo

机构信息

Department of Nuclear Medicine, Peking University First Hospital, Beijing 100034, China.

Department of Nuclear Medicine, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan Province 450052, China.

出版信息

Mol Pharm. 2025 Apr 7;22(4):2266-2275. doi: 10.1021/acs.molpharmaceut.5c00069. Epub 2025 Mar 9.

DOI:10.1021/acs.molpharmaceut.5c00069
PMID:40059341
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11978314/
Abstract

Trop2 exhibits significantly elevated expression in numerous solid malignancies, playing a crucial role in tumor advancement, whereas its presence in healthy tissues is minimal. In this study, we investigated Trop2 expression in bladder cancer models using [Cu]Cu-NOTA-Trodelvy for immunoPET imaging. In HT-1376 models, [Cu]Cu-NOTA-Trodelvy effectively visualized tumor as early as 12 h p.i. (10.30 ± 1.45% ID/g), with tumor uptake increasing and peaking at 48 h p.i. (13.73 ± 1.16% ID/g), highlighting its potential for tumor imaging. Control groups also demonstrated low tumor uptake (5.27 ± 1.14% ID/g at 48 h in the blocking group; 6.33 ± 0.74% ID/g at 48 h in UM-UC-3; 4.50 ± 0.30% ID/g at 48 h in the [Cu]Cu-NOTA-IgG group). Long-term fluorescence imaging further confirmed the tumor uptake rate in the IRDye 800CW-Trodelvy group was significantly higher than in the IRDye 800CW-Trodelvy blockade group ( < 0.001). Our findings demonstrated that [Cu]Cu-NOTA-Trodelvy enables specific and prolonged tumor accumulation in bladder cancer models, providing precise and noninvasive monitoring of Trop2 expression.

摘要

Trop2在众多实体恶性肿瘤中表达显著升高,在肿瘤进展中起关键作用,而在健康组织中的表达极少。在本研究中,我们使用[铜]铜- NOTA - Trodelvy进行免疫PET成像,研究了膀胱癌模型中Trop2的表达。在HT - 1376模型中,[铜]铜- NOTA - Trodelvy在注射后12小时即可有效显示肿瘤(10.30±1.45% ID/g),肿瘤摄取量在注射后48小时增加并达到峰值(13.73±1.16% ID/g),突出了其在肿瘤成像方面的潜力。对照组的肿瘤摄取量也较低(阻断组在48小时时为5.27±1.14% ID/g;UM - UC - 3在48小时时为6.33±0.74% ID/g;[铜]铜- NOTA - IgG组在48小时时为4.50±0.30% ID/g)。长期荧光成像进一步证实,IRDye 800CW - Trodelvy组的肿瘤摄取率显著高于IRDye 800CW - Trodelvy阻断组(<0.001)。我们的研究结果表明,[铜]铜- NOTA - Trodelvy能够在膀胱癌模型中实现特异性和长时间的肿瘤蓄积,为Trop2表达提供精确且无创的监测。

相似文献

1
ImmunoPET Imaging of Trop2 Expression in Bladder Cancer Using [Cu]Cu-NOTA-Trodelvy.使用[铜]Cu-NOTA-Trodelvy对膀胱癌中Trop2表达进行免疫正电子发射断层显像。
Mol Pharm. 2025 Apr 7;22(4):2266-2275. doi: 10.1021/acs.molpharmaceut.5c00069. Epub 2025 Mar 9.
2
ImmunoPET imaging of Trop2 expression in triple-negative breast cancer using [Cu]Cu-NOTA-Trodelvy-F(ab').使用[铜]Cu-NOTA-Trodelvy-F(ab')对三阴性乳腺癌中Trop2表达进行免疫正电子发射断层扫描成像
Eur J Nucl Med Mol Imaging. 2025 Feb 25. doi: 10.1007/s00259-025-07167-5.
3
Preclinical evaluation of zirconium-89 labeled anti-Trop2 antibody-drug conjugate (Trodelvy) for imaging in gastric cancer and triple-negative breast cancer.用于胃癌和三阴性乳腺癌成像的锆-89标记抗Trop2抗体药物偶联物(Trodelvy)的临床前评估
Eur J Nucl Med Mol Imaging. 2025 Jan 29. doi: 10.1007/s00259-025-07106-4.
4
ImmunoPET Imaging of Nectin4 Expression in Gastric and Bladder Cancer Using [Cu]Cu-NOTA-Padcev.使用[Cu]Cu-NOTA-Padcev对胃癌和膀胱癌中Nectin4表达进行免疫正电子发射断层显像
Mol Pharm. 2025 Jun 2;22(6):3468-3478. doi: 10.1021/acs.molpharmaceut.5c00469. Epub 2025 May 8.
5
Immuno-PET Imaging of CD93 Expression with Cu-Radiolabeled NOTA-mCD93 ([Cu]Cu-NOTA-mCD93) and Insulin-Like Growth Factor Binding Protein 7 ([Cu]Cu-NOTA-IGFBP7).使用铜放射性标记的NOTA-mCD93([Cu]Cu-NOTA-mCD93)和胰岛素样生长因子结合蛋白7([Cu]Cu-NOTA-IGFBP7)对CD93表达进行免疫正电子发射断层显像。
Mol Pharm. 2024 Dec 2;21(12):6411-6422. doi: 10.1021/acs.molpharmaceut.4c00983. Epub 2024 Nov 12.
6
Pre-clinical evaluation of immunoPET imaging using agonist CD40 monoclonal antibody in pancreatic tumor-bearing mice.免疫 PET 成像在荷胰腺肿瘤小鼠中激动型 CD40 单克隆抗体的临床前评估。
Nucl Med Biol. 2021 Jul-Aug;98-99:8-17. doi: 10.1016/j.nucmedbio.2021.04.001. Epub 2021 Apr 21.
7
ImmunoPET Imaging of CD146 in Murine Models of Intrapulmonary Metastasis of Non-Small Cell Lung Cancer.免疫 PET 显像在非小细胞肺癌肺内转移鼠模型中的 CD146 研究
Mol Pharm. 2017 Oct 2;14(10):3239-3247. doi: 10.1021/acs.molpharmaceut.7b00216. Epub 2017 Sep 6.
8
Development and Preclinical Evaluation of [Cu]Cu-NOTA-ABDB6: A CD70 and Albumin Dual-Binding Tracer with Improved Pharmacokinetics.[铜]铜-NOTA-ABDB6的研发及临床前评估:一种具有改善药代动力学的CD70与白蛋白双结合示踪剂
J Nucl Med. 2025 Apr 1;66(4):552-558. doi: 10.2967/jnumed.124.268835.
9
Theranostic application of Cu/Lu-labeled anti-Trop2 monoclonal antibody in pancreatic cancer tumor models.铜/镥标记抗 Trop2 单克隆抗体在胰腺癌肿瘤模型中的诊断与治疗应用。
Eur J Nucl Med Mol Imaging. 2022 Dec;50(1):168-183. doi: 10.1007/s00259-022-05954-y. Epub 2022 Sep 5.
10
Immuno-PET Imaging of EGFR with Cu-NOTA Panitumumab in Subcutaneous and Metastatic Nonsmall Cell Lung Cancer Xenografts.EGFR 免疫 PET 显像:应用 Cu-NOTA 帕尼单抗在皮下和转移性非小细胞肺癌异种移植瘤中的研究
Mol Pharm. 2024 Nov 4;21(11):5797-5806. doi: 10.1021/acs.molpharmaceut.4c00823. Epub 2024 Oct 15.

引用本文的文献

1
Noninvasive ImmunoPET imaging of PD-L1 expression in non-small cell lung cancer and bladder cancer using [Zr]Zr-DFO-Durvalumab.使用[Zr]Zr-DFO-度伐利尤单抗对非小细胞肺癌和膀胱癌中PD-L1表达进行无创免疫正电子发射断层显像。
Colloids Surf A Physicochem Eng Asp. 2025 Oct 20;723. doi: 10.1016/j.colsurfa.2025.137332. Epub 2025 May 29.
2
[Cu]Cu-NOTA-EV-F(ab') Enables Same-Day Immuno-PET Imaging of Nectin-4 in Triple-Negative Breast and Urothelial Bladder Cancers.[铜]铜- NOTA - EV - F(ab')可实现三阴性乳腺癌和尿路上皮膀胱癌中NECTIN - 4的同日免疫正电子发射断层显像。
J Nucl Med. 2025 Sep 2;66(9):1365-1371. doi: 10.2967/jnumed.125.270132.
3
[Zr]Zr-DFO-Trodelvy immunoPET for noninvasive Trop2 imaging in bladder cancer.[锆]锆-去铁胺-戈沙妥珠单抗免疫正电子发射断层扫描用于膀胱癌中Trop2的无创成像
Am J Nucl Med Mol Imaging. 2025 Jun 25;15(3):87-96. doi: 10.62347/KKEE6954. eCollection 2025.
4
Rapid and specific immunoPET imaging of Nectin-4 in gastric cancer and non-small cell lung cancer using [Cu]Cu-NOTA-EV-F(ab').使用[铜]铜-诺他-埃夫-F(ab')对胃癌和非小细胞肺癌中的Nectin-4进行快速且特异性的免疫正电子发射断层显像
Eur J Nucl Med Mol Imaging. 2025 Jun 21. doi: 10.1007/s00259-025-07402-z.
5
ImmunoPET Imaging of Nectin4 Expression in Gastric and Bladder Cancer Using [Cu]Cu-NOTA-Padcev.使用[Cu]Cu-NOTA-Padcev对胃癌和膀胱癌中Nectin4表达进行免疫正电子发射断层显像
Mol Pharm. 2025 Jun 2;22(6):3468-3478. doi: 10.1021/acs.molpharmaceut.5c00469. Epub 2025 May 8.

本文引用的文献

1
ImmunoPET imaging of Trop2 expression in triple-negative breast cancer using [Cu]Cu-NOTA-Trodelvy-F(ab').使用[铜]Cu-NOTA-Trodelvy-F(ab')对三阴性乳腺癌中Trop2表达进行免疫正电子发射断层扫描成像
Eur J Nucl Med Mol Imaging. 2025 Feb 25. doi: 10.1007/s00259-025-07167-5.
2
Preclinical evaluation of zirconium-89 labeled anti-Trop2 antibody-drug conjugate (Trodelvy) for imaging in gastric cancer and triple-negative breast cancer.用于胃癌和三阴性乳腺癌成像的锆-89标记抗Trop2抗体药物偶联物(Trodelvy)的临床前评估
Eur J Nucl Med Mol Imaging. 2025 Jan 29. doi: 10.1007/s00259-025-07106-4.
3
CD38-specific immunoPET imaging for multiple myeloma diagnosis and therapeutic monitoring: preclinical and first-in-human studies.用于多发性骨髓瘤诊断和治疗监测的CD38特异性免疫正电子发射断层显像:临床前和首次人体研究。
Eur J Nucl Med Mol Imaging. 2025 Apr;52(5):1791-1804. doi: 10.1007/s00259-024-07036-7. Epub 2024 Dec 27.
4
Trop-2 and Ephrin B2 expression in urothelial carcinoma with divergent differentiation and aggressive urothelial carcinoma subtypes.Trop-2和Ephrin B2在具有不同分化的尿路上皮癌及侵袭性尿路上皮癌亚型中的表达
Am J Clin Pathol. 2025 Apr 19;163(4):618-628. doi: 10.1093/ajcp/aqae161.
5
Immuno-PET Imaging of CD93 Expression with Cu-Radiolabeled NOTA-mCD93 ([Cu]Cu-NOTA-mCD93) and Insulin-Like Growth Factor Binding Protein 7 ([Cu]Cu-NOTA-IGFBP7).使用铜放射性标记的NOTA-mCD93([Cu]Cu-NOTA-mCD93)和胰岛素样生长因子结合蛋白7([Cu]Cu-NOTA-IGFBP7)对CD93表达进行免疫正电子发射断层显像。
Mol Pharm. 2024 Dec 2;21(12):6411-6422. doi: 10.1021/acs.molpharmaceut.4c00983. Epub 2024 Nov 12.
6
Sacituzumab govitecan in metastatic triple-negative breast cancer patients treated at Institut Curie Hospitals: efficacy, safety, and impact of brain metastases.在居里研究所医院治疗的转移性三阴性乳腺癌患者中使用 sacituzumab govitecan:疗效、安全性和脑转移的影响。
Breast Cancer. 2024 Jul;31(4):572-580. doi: 10.1007/s12282-024-01565-7. Epub 2024 Apr 10.
7
Enhanced Theranostic Efficacy of Zr and Lu-Labeled Aflibercept in Renal Cancer: A Viable Option for Clinical Practice.Zr 和 Lu 标记的阿柏西普在肾癌中的治疗效果增强:临床应用的可行选择。
Mol Pharm. 2024 May 6;21(5):2544-2554. doi: 10.1021/acs.molpharmaceut.4c00084. Epub 2024 Apr 8.
8
ImmunoPET imaging of Trop2 in patients with solid tumours.免疫 PET 显像在实体瘤患者中的 Trop2 研究。
EMBO Mol Med. 2024 May;16(5):1143-1161. doi: 10.1038/s44321-024-00059-5. Epub 2024 Apr 2.
9
Noninvasive PET imaging of tumor PD-L1 expression with Cu-labeled Durvalumab.用铜标记的度伐鲁单抗对肿瘤程序性死亡受体配体1(PD-L1)表达进行无创正电子发射断层扫描(PET)成像
Am J Nucl Med Mol Imaging. 2024 Feb 20;14(1):31-40. doi: 10.62347/HUQD8000. eCollection 2024.
10
Advances in diagnosis and treatment of bladder cancer.膀胱癌的诊断与治疗进展。
BMJ. 2024 Feb 12;384:e076743. doi: 10.1136/bmj-2023-076743.